Literature DB >> 30085243

Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease.

Frida Emanuelsson1,2, Børge G Nordestgaard2,3,4, Marianne Benn1,2,4.   

Abstract

Context: Individuals with familial hypercholesterolemia (FH) have a high risk of coronary artery disease, but their risk of peripheral arterial disease (PAD) and chronic kidney disease (CKD) is unknown. Objective: In individuals with clinical FH, we tested the hypotheses (1) that the risks of PAD and CKD are elevated and (2) that low ankle-brachial index (ABI) and estimated glomerular filtration rate (eGFR) are associated with a high risk of myocardial infarction. Design and Setting: Prospective cohort study of the general population. Participants: A total of 106,172 individuals, of whom 7109 were diagnosed with FH. Main Outcome Measures: PAD, CKD, and myocardial infarction.
Results: Compared with individuals with unlikely FH, multivariable adjusted ORs (95% CIs) of PAD were 1.84 (1.70 to 2.00) in those with possible FH and 1.36 (1.00 to 1.84) in individuals with probable/definite FH. For CKD, the corresponding ORs (95% CIs) were 1.92 (1.78 to 2.07) and 2.42 (1.86 to 3.26). Compared with individuals with unlikely FH and ABI >0.9, the multivariable adjusted hazard ratio (95% CI) of myocardial infarction was 4.60 (2.36 to 8.97) in those with possible/probable/definite FH and ABI ≤0.9. Compared with individuals with unlikely FH and eGFR ≥60 mL/min/1.73 m2, the corresponding value was 2.19 (1.71 to 2.82) in those with possible/probable/definite FH and eGFR <60 mL/min/1.73 m2. Conclusions: Individuals with clinical FH have increased risks of PAD and CKD, and low ABI and eGFR are associated with high risk of myocardial infarction. Consequently, individuals with FH should be screened for PAD and CKD, and ABI and eGFR may be used as prognostic tools in the management and treatment of FH to identify those at very high risk of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30085243     DOI: 10.1210/jc.2018-01058

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Serum Cadmium Levels and Risk of Metabolic Syndrome: A Cross-Sectional Study.

Authors:  Nour Ayoub; Hiba Mantash; Hassan R Dhaini; Abbas Mourad; Mohammad Hneino; Zeina Daher
Journal:  Biol Trace Elem Res       Date:  2021-01-06       Impact factor: 3.738

Review 2.  Novel Therapies for Alport Syndrome.

Authors:  Efren Chavez; Juanly Rodriguez; Yelena Drexler; Alessia Fornoni
Journal:  Front Med (Lausanne)       Date:  2022-04-25

Review 3.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

4.  Enzymatic Reactions in a Lab-on-Valve System: Cholesterol Evaluations.

Authors:  Jucineide S Barbosa; Marieta L C Passos; M das Graças A Korn; M Lúcia M F S Saraiva
Journal:  Molecules       Date:  2019-08-09       Impact factor: 4.411

5.  Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania.

Authors:  Cristiana-Elena Vlad; Liliana Foia; Laura Florea; Irina-Iuliana Costache; Andreea Covic; Roxana Popescu; Delia Reurean-Pintilei; Adrian Covic
Journal:  Lipids Health Dis       Date:  2021-01-11       Impact factor: 3.876

6.  MIF rs755622 and IL6 rs1800795 Are Implied in Genetic Susceptibility to End-Stage Renal Disease (ESRD).

Authors:  Marco Guarneri; Letizia Scola; Rosa Maria Giarratana; Manuela Bova; Caterina Carollo; Loredana Vaccarino; Leonardo Calandra; Domenico Lio; Carmela Rita Balistreri; Santina Cottone
Journal:  Genes (Basel)       Date:  2022-01-25       Impact factor: 4.096

7.  Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion.

Authors:  Takeo Ishii; Masatsune Ogura; Haruka Nakamori; Mika Hori; Mariko Harada-Shiba; Kouichi Tamura; Kunio Oyama
Journal:  CEN Case Rep       Date:  2021-06-07

8.  The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.

Authors:  Alexey N Meshkov; Alexandra I Ershova; Anna V Kiseleva; Svetlana A Shalnova; Oxana M Drapkina; Sergey A Boytsov
Journal:  J Pers Med       Date:  2021-05-24

Review 9.  The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction.

Authors:  Mengyuan Ge; Flavia Fontanesi; Sandra Merscher; Alessia Fornoni
Journal:  Front Physiol       Date:  2020-07-07       Impact factor: 4.566

10.  Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study.

Authors:  Ralph K Akyea; Nadeem Qureshi; Joe Kai; Simon de Lusignan; Julian Sherlock; Christopher McGee; Stephen Weng
Journal:  BJGP Open       Date:  2020-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.